Takayasu arteritis (TAK) refractory to conventional disease-modifying anti-rheumatic drugs
(DMARDs) is commonly treated with biologic DMARDs such as tocilizumab or tumor …

Objective To present the pooled quantitative evidence of baseline characteristics and
clinical outcomes of tocilizumab (TCZ) in patients with refractory Takayasu arteritis (TAK) …

Objective To investigate the long-term efficacy and safety of the IL-6 receptor antibody
tocilizumab in patients with Takayasu arteritis (TAK). Methods Patients completing the …

Objective To investigate the efficacy and safety of the interleukin-6 receptor antibody
tocilizumab in patients with Takayasu arteritis (TAK). Methods Patients with TAK who had …

Objectives We evaluated the real-world tolerability and effectiveness of tocilizumab in
Japanese patients with Takayasu arteritis (TAK). Methods Patients with TAK who had not …

Objective This study aimed to compare the efficacy and safety of adalimumab (ADA) vs
tocilizumab (TCZ) in patients with Takayasu arteritis (TAK). Methods This was a randomized …

Objective. The aim of our study was to evaluate the safety and the efficacy of tocilizumab
(TCZ) for refractory Takayasu arteritis (TA). Methods. We retrospectively assessed the …

Objective To assess the safety and the efficacy of TNF-α antagonists and tocilizumab in
patients with Takayasu arteritis (TAK). Methods A total of 209 patients with TAK [median age …

OBJECTIVE: We aimed to systematically review biological agents' efficacy and safety in
patients with Takayasu arteritis (TAK). MATERIALS AND METHODS: A systematic literature …

Objectives To assess the efficacy of tocilizumab in patients with Takayasu arteritis (TA).
Methods We conducted a retrospective multicenter study in 46 TA patients treated with …